During the past decade, Investigacion en Salud y Metabolismo S.C conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 11 clinical trials were completed, i.e. on average, 57.9% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 8 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Investigacion en Salud y Metabolismo S.C" #1 sponsor was "Eli Lilly and Company" with 15 trials, followed by "Boehringer Ingelheim" with 3 trials sponsored, "Pfizer" with 2 trials sponsored, "Kowa Research Institute, Inc." with 1 trials sponsored and "Resverlogix Corp" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Investigacion en Salud y Metabolismo S.C" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator, "ICON plc" with 1 trials as a collaborator, "Medidata Solutions" with 1 trials as a collaborator and "PPD" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Investigacion en Salud y Metabolismo S.C" are "Diabetes Mellitus, Type 2" (6 trials), "Type 2 Diabetes" (5 trials), "Type 2 Diabetes Mellitus" (4 trials), "Obesity" (3 trials) and "Cardiovascular Disease" (2 trials). Many other conditions were trialed in "Investigacion en Salud y Metabolismo S.C" in a lesser frequency.

Most popular intervention types in "Investigacion en Salud y Metabolismo S.C" are "Drug" (22 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Tirzepatide" (9 trials), "Dulaglutide" (3 trials), "Insulin Degludec" (2 trials) and "Insulin Efsitora Alfa" (2 trials). Other intervention names were less common.

The vast majority of trials in "Investigacion en Salud y Metabolismo S.C" are 22 trials for "All" genders.

Currently, there are NaN active trials in "Investigacion en Salud y Metabolismo S.C". undefined are not yet recruiting, 6 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Investigacion en Salud y Metabolismo S.C, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Investigacion en Salud y Metabolismo S.C, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 0 trials that are defined as “Not Applicable".